These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 17538545)

  • 21. Effect of antioxidants on mitochondrial function in HIV-1-related lipoatrophy: a pilot study.
    Milazzo L; Menzaghi B; Caramma I; Nasi M; Sangaletti O; Cesari M; Zanone Poma B; Cossarizza A; Antinori S; Galli M
    AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1207-14. PubMed ID: 20977356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndrome.
    Nolan D; Mallal S
    J HIV Ther; 2004 May; 9(2):34-40. PubMed ID: 15238874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial.
    Valantin MA; Lanoy E; Bentata M; Kalmykova O; Boutekadjirt A; Allavena C; Rozenbaum W; Peytavin G; Amellal B; Calvez V; Costagliola D; Katlama C;
    HIV Med; 2008 Oct; 9(8):625-35. PubMed ID: 18624724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy.
    Cavalcanti RB; Raboud J; Shen S; Kain KC; Cheung A; Walmsley S
    J Infect Dis; 2007 Jun; 195(12):1754-61. PubMed ID: 17492590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-line therapy and mitochondrial damage: different nucleosides, different findings.
    Blanco F; García-Benayas T; José de la Cruz J; González-Lahoz J; Soriano V
    HIV Clin Trials; 2003; 4(1):11-9. PubMed ID: 12577192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic approaches to combating lipoatrophy: do they work?
    Martin A; Mallon PW
    J Antimicrob Chemother; 2005 May; 55(5):612-5. PubMed ID: 15761072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The influence of HIV infection and antiretroviral therapy on the mitochondrial membrane potential of peripheral mononuclear cells.
    Sternfeld T; Schmid M; Tischleder A; Mudra S; Schlamp A; Kost BP; Gruber R; Youle M; Bogner JR; Goebel FD
    Antivir Ther; 2007; 12(5):769-78. PubMed ID: 17713160
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular risk and body-fat abnormalities in HIV-infected adults.
    Grinspoon S; Carr A
    N Engl J Med; 2005 Jan; 352(1):48-62. PubMed ID: 15635112
    [No Abstract]   [Full Text] [Related]  

  • 29. Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy.
    Sievers M; Walker UA; Sevastianova K; Setzer B; Wågsäter D; Eriksson P; Yki-Järvinen H; Sutinen J
    J Infect Dis; 2009 Jul; 200(2):252-62. PubMed ID: 19519254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.
    Moyle GJ; Sabin CA; Cartledge J; Johnson M; Wilkins E; Churchill D; Hay P; Fakoya A; Murphy M; Scullard G; Leen C; Reilly G;
    AIDS; 2006 Oct; 20(16):2043-50. PubMed ID: 17053350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome.
    Feldt T; Oette M; Kroidl A; Goebels K; Fritzen R; Kambergs J; Kappert G; Vogt C; Wettstein M; Häussinger D
    Infection; 2006 Apr; 34(2):55-61. PubMed ID: 16703293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy.
    Hulgan T; Tebas P; Canter JA; Mulligan K; Haas DW; Dubé M; Grinspoon S; Robbins GK; Motsinger AA; Kallianpur AR;
    J Infect Dis; 2008 Mar; 197(6):858-66. PubMed ID: 18419350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A 6-month interruption of antiretroviral therapy improves adipose tissue function in HIV-infected patients: the ANRS EP29 Lipostop Study.
    Kim MJ; Leclercq P; Lanoy E; Cervera P; Antuna-Puente B; Maachi M; Dorofeev E; Slama L; Valantin MA; Costagliola D; Lombes A; Bastard JP; Capeau J
    Antivir Ther; 2007; 12(8):1273-83. PubMed ID: 18240867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of highly active antiretroviral therapy associated metabolic abnormalities and lipodystrophy in HIV infected patients.
    Feleke Y; Fekade D; Mezegebu Y
    Ethiop Med J; 2012 Jul; 50(3):221-30. PubMed ID: 23409405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Skeletal muscle mitochondrial DNA content and aerobic metabolism in patients with antiretroviral therapy-associated lipoatrophy.
    Sutinen J; Laaksonen MS; Walker UA; Setzer B; Kemppainen J; Nuutila P; Yki-Järvinen H
    J Antimicrob Chemother; 2010 Jul; 65(7):1497-504. PubMed ID: 20444746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda.
    van Griensven J; De Naeyer L; Mushi T; Ubarijoro S; Gashumba D; Gazille C; Zachariah R
    Trans R Soc Trop Med Hyg; 2007 Aug; 101(8):793-8. PubMed ID: 17467756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Uridine abrogates the adverse effects of antiretroviral pyrimidine analogues on adipose cell functions.
    Walker UA; Auclair M; Lebrecht D; Kornprobst M; Capeau J; Caron M
    Antivir Ther; 2006; 11(1):25-34. PubMed ID: 16518957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA.
    Valantin MA; Aubron-Olivier C; Ghosn J; Laglenne E; Pauchard M; Schoen H; Bousquet R; Katz P; Costagliola D; Katlama C
    AIDS; 2003 Nov; 17(17):2471-7. PubMed ID: 14600518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of lipoatrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy.
    Hartman K; Verweel G; de Groot R; Hartwig NG
    Pediatr Infect Dis J; 2006 May; 25(5):427-31. PubMed ID: 16645507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mitochondrial impact of human immunodeficiency virus and antiretrovirals on infected pediatric patients with or without lipodystrophy.
    Morén C; Noguera-Julian A; Rovira N; Corrales E; Garrabou G; Hernández S; Nicolás M; Tobías E; Cardellach F; Miró O; Fortuny C
    Pediatr Infect Dis J; 2011 Nov; 30(11):992-5. PubMed ID: 21697766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.